



FOR IMMEDIATE RELEASE

Contact: Mark N. Schwartz, CEO
(651) 687-9999

Hypertension Diagnostics Announces FY 2007 Second Quarter Results

ST. PAUL, MN – February 14, 2007 – Hypertension Diagnostics, Inc. (OTC: HDII.OB), today announced financial results for the second quarter of fiscal year 2007 ended December 31, 2006.

Revenue for the quarter totaled \$548,723 compared to \$541,106 in the prior year's second quarter ended December 31, 2005. However, in the prior year's second quarter, the Company's sales benefited from a \$135,000 sale to an international distributor which did not recur in this year's second quarter. Excluding the international sales results in the prior year, the \$548,723 of sales in the current quarter are up 26% from the adjusted results in the prior year's quarter. The Company incurred a net loss of \$225,404 for the current quarter or \$(.01) per share compared with a net loss of \$283,927 for the prior year's quarter or \$(.01) per share. Included in the net loss of \$225,404 for the quarter are total non-cash charges (expenses associated mainly with stock compensation, depreciation, stock options) of \$166,072. The Company reported a cash balance of \$1,441,378 on December 31, 2006.

For the six month period ended December 31, 2006, total revenue was \$971,208, compared to \$922,022 for the same period one year ago, a 5.3% increase. For the six month period ended December 31, 2006, the Company incurred a net loss of \$413,485, or \$(.01) per share, compared with a net loss of \$621,144, or \$(.02) per share, for the same period one year ago.

"We are extremely pleased with the financial results for the quarter, which are among the strongest quarterly results that the Company has seen in recent years," said Mark N. Schwartz, Chairman and CEO. "The prior year's quarter had the benefit of an international shipment and four full time sales reps, while the current quarter consisted totally of domestic sales and the Company only had three full time sales reps, two of whom have been with the Company less than six months. We believe these results provide evidence of the fact that the Company can identify and develop new markets quickly, an important component to our future growth," commented Schwartz.

Forward-looking statements in this press release are made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The Company wishes to caution readers not to place undue reliance on any forward-looking statements and to recognize that the statements are not a prediction of actual future results. Actual results could differ materially from those presented and anticipated in the forward-looking statements due to the risks and uncertainties set forth in the Company's 2006 Annual Report on Form 10-KSB, and subsequent Quarterly Reports on Form 10-QSB, all of which were filed with the U.S. Securities and Exchange Commission, as well as others not now anticipated.

Hypertension Diagnostics, Inc.
Summary Financial Data

Statements of Operations (Unaudited)

	Three Months Ended December 31		Six Months Ended December 31	
	2006	2005	2006	2006
Revenue:				
Equipment sales	\$ 476,505	\$ 433,736	\$ 809,806	\$ 685,658
Equipment rental	65,407	105,614	140,585	227,144
Service/contract income	6,811	1,756	20,817	9,220
	<u>548,723</u>	<u>541,106</u>	<u>971,208</u>	<u>922,022</u>
Cost of Sales	13,330	29,993	33,575	62,493
Gross Profit	<u>535,393</u>	<u>511,113</u>	<u>937,633</u>	<u>859,529</u>
Selling, general and administrative expenses	774,954	804,239	1,386,960	1,501,348
Operating Loss	(239,561)	(293,126)	(449,327)	(641,819)
Other Income (Expense):				
Interest income	14,157	9,199	27,743	20,675
Gain on sale of property and equipment	-	-	8,099	-
Total Other Income	<u>14,157</u>	<u>9,199</u>	<u>35,842</u>	<u>20,675</u>
Net Loss	<u>\$ (225,404)</u>	<u>\$ (283,927)</u>	<u>\$ (413,485)</u>	<u>\$ (621,144)</u>
Basic and Diluted Net Loss per Share	\$ (.01)	\$ (.01)	\$ (.01)	\$ (.02)
Weighted Average Shares Outstanding	39,846,547	33,264,362	40,001,826	33,097,633

Balance Sheet Data

	December 31, 2006 (Unaudited)	June 30, 2006 (Audited)
Cash and cash equivalents	\$ 1,441,378	\$ 1,722,913
Total current assets	1,935,229	2,257,390
Total assets	1,999,436	2,345,949
Total current liabilities	522,040	489,081
Accumulated deficit	(26,391,804)	(25,978,319)
Total shareholders' equity	1,465,444	1,840,414
	# # #	

CVProfilor is a registered trademark of Hypertension Diagnostics, Inc.
Hypertension Diagnostics, HDI/*PulseWave*, *PulseWave* and CVProfile are trademarks of Hypertension Diagnostics, Inc. All rights reserved.
Website: www.hdii.com